Letter by Chang et al Regarding Article, “Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the article, “Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial,” by Fouda et al1 published in Stroke. Although its efficacy in improving clinical outcome after ischemic stroke is unclear,2,3 minocycline’s safety profile in ischemic stroke is well established. However, until now, its safety profile and clinical efficacy in intracerebral hemorrhage (ICH) remained unclear.
The search for neuroprotectants in ICH that improve clinical outcome is particularly important in the current landscape because recent trials targeting hematoma expansion have failed to show clinical benefit. Minocycline has been shown to be an MMP-9 (matrix metalloproteinase-9) inhibitor. This allows for a potential mechanism …